Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
- Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
- Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
- Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
- Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.